IRF1 and non-small cell lung carcinoma: We found that GAS5 modulated the infiltration of macrophages and T cells by activating the type I interferon signaling via MYBBP1A-p53/IRF1 axis in NSCLC, which might enhance immunotherapy efficacy, indicating a promising predictive and therapeutic target for NSCLC.